Prevalencia y factores de riesgo para enterocolitis necrosante en recién nacidos de 1,000 a 1,500 g en la unidad de cuidados intensivos neonatales del Hospital Universitario Dr. José Eleuterio González desde el 1 de agosto del 2005 hasta el 31 de julio del 2006

Antecedentes: la enterocolitis necrosante es la enfermedad gastrointestinal médica y quirúrgica más frecuente de la etapa neonatal. Objetivo: conocer su prevalencia y sus factores de riesgo en recién nacidos de 1,000 a 1,500 g en la unidad de cuidados intensivos eonatales del Hospital Universitario Dr. José Eleuterio González. Material y métodos: estudio observacional, analítico, retrospectivo de casos y controles. Se recopilaron los datos de los expedientes clínicos de los pacientes nacidos en el Hospital Universitario durante el periodo del 1 de agosto del 2005 al 31 de julio del 2006 con peso de 1,000 a 1,500 g. Se excluyeron pacientes que nacieron en otro hospital o que tuvieran malformaciones congénitas. Se analizaron los datos mediante las pruebas de la χ2, la t de Student y razón de momios. Resutados: de los 55 pacientes que reunieron los criterios de inclusión, 18% tuvieron enterocolitis necrosante grado II o mayor. Se encontraron como factores de riesgo con significación estadística al Apgar de 0 a 6 al primer minuto, uso de presión positiva continua nasal, uso de aminofi lina y sepsis tardía (p < 0.05). Conclusiones: su prevalencia es mayor en el hospital en donde se efectuó el presente estudio que la reportada en países desarrollados o en hospitales privados de países en vías de desarrollo, pero con menor mortalidad. Los factores de riesgo con significación estadística fueron los relacionados con episodios de isquemia, reperfusión e infección.

Frequency of metabolic syndrome in women treated at the Menopause Clinic of the “Dr. José Eleuterio González” University Hospital of the UANL in Northeastern Mexico

Objectives: To determine the frequency of metabolic syndrome (MS) in patients with menopause, and to compare the incidence of MS between surgical and natural menopause. Methods: This was an observational, longitudinal, descriptive, retrospective, unblinded study of cases seen at the Menopause Clinic of the University Hospital “Dr. José eleuterio González” of the Universidad Autónoma de Nuevo León from March 2009 to December 2011. The frequency of MS was determined based on Adult Treatment Panel III (ATPIII) classiication. Results: at the end of the study, 391 patients were evaluated. The mean age was 50.1 years. We found a frequency of MS of 38.1%, the risk factor most often found was low HDL cholesterol (62.5%), followed by obesity (46.5%), hypercholesterolemia (42.3%), hyperglycemia (11.5%), and hypertension (7.7%). The incidence of natural and surgical menopause was 37.6% vs. 39.2% respectively; however, the result was not statistically signiicant (p = 0.093). Conclusions: Patients with menopause are at increased risk of developing MS. it is important to detect MS early in this of patients, when they have one risk factor to avoid complications which may trigger the syndrome. We recommend screening for MS during perimenopause, in order to detect and try to delay it in a timely manner and recommend primary prevention (diet and exercise), or secondary prevention in cases with one or more risk factors.

Frequency of metabolic syndrome in women treated at the Menopause Clinic of the “Dr. José Eleuterio González” University Hospital of the UANL in Northeastern Mexico

Objectives: To determine the frequency of metabolic syndrome (MS) in patients with menopause, and to compare the incidence of MS between surgical and natural menopause. Methods: This was an observational, longitudinal, descriptive, retrospective, unblinded study of cases seen at the Menopause Clinic of the University Hospital “Dr. José eleuterio González” of the Universidad Autónoma de Nuevo León from March 2009 to December 2011. The frequency of MS was determined based on Adult Treatment Panel III (ATPIII) classiication. Results: at the end of the study, 391 patients were evaluated. The mean age was 50.1 years. We found a frequency of MS of 38.1%, the risk factor most often found was low HDL-cholesterol (62.5%), followed by obesity (46.5%), hypercholesterolemia (42.3%), hyperglycemia (11.5%), and hypertension (7.7%). The incidence of natural and surgical menopause was 37.6% vs. 39.2% respectively; however, the result was not statistically signiicant (p = 0.093). Conclusions: Patients with menopause are at increased risk of developing MS. it is important to detect MS early in this of patients, when they have one risk factor to avoid complications which may trigger the syndrome. We recommend screening for MS during perimenopause, in order to detect and try to delay it in a timely manner and recommend primary prevention (diet and exercise), or secondary prevention in cases with one or more risk factors.

Biobanks: Experience of the School of Medicine and the “Dr. José Eleuterio González” University Hospital of the Universidad Autónoma de Nuevo León

Medical research has greatly beneited from molecular biology and increasingly relies on tools from the “omics” disciplines (mainly genomics, transcriptomics, proteomics and metabolomics). The availability of biological samples preserved with high quality standards is a sine qua non condition for such studies and their repositories are referred to as biobanks. Biobanks support the transportation, storage, preservation, and initial pathological and analytical examinations of biospecimens, as well as the protection of relevant information and the comparison of clinical and laboratory findings. A biobank facility is one of the most valuable tools the academic medicine organizations can offer to their researchers to improve the competitiveness of their current and future medical research. it acts as an essential bridge and an effective catalyst for research synergies between basic and clinical sciences, and it can be potentiated with efforts to raise funds for acquiring and maintaining cutting-edge analytical infrastructure to better serve its clinical, pharmaceutical and biotech clients.